HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao

China Healthcare Weekly (Aug.4)- Taiji Group & China TCM, TCM Formula Granules VBP, Keymed's Trouble

China Healthcare Weekly (Aug.18)- COVID Is Here, BIOSECURE Act Update, Livzon Deserves More Patience

Ascentage Pharma (6855.HK) - May Not Survive "This Winter"

Hutchmed China Ltd (13.HK/​​HCM.US) - High Growth Is Expected from 2024 to 2026

Asia Cement China (743.HK) Privatization- There May Be "Surprises" Despite Disappointing Offer Price

Asia Cement (743 HK): $3.22/Share Offer - Really?

China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait

Equity Bottom-Up

Ascentage Pharma Group Corp / Equity Bottom-Up

<ul>
<li>Ascentage was originally in an extremely difficult situation, but the cooperation with Takeda turned things around. Ascentage has obtained urgently needed cash flow to solve the survival problem.</li>
<li>At this stage, it’s possible for Ascentage to hit about 50% market value of HCM.  Investors are interested to know if APG-2575 would also be out-licensed, which however is not easy.</li>
<li>Ascentage’s current strength isn’t sufficient to self-build sales system. While this deal is a good start, if Ascentage still chooses to do commercialization on its own, it’s time to sell. </li>
</ul>


Ascentage was originally in an extremely difficult situation, but the cooperation with Takeda turned things around. Ascentage has obtained urgently needed cash flow to solve the survival problem.
At this stage, it’s possible for Ascentage to hit about 50% market value of HCM.  Investors are interested to know if APG-2575 would also be out-licensed, which however is not easy.
Ascentage’s current strength isn’t sufficient to self-build sales system. While this deal is a good start, if Ascentage still chooses to do commercialization on its own, it’s time to sell. 


Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path